

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of claims:

1. (Previously Presented) A pharmaceutical composition useful for the treatment or control of bacterial infections by parenteral administration, the composition comprising effective amounts of (a) piperacillin or a pharmaceutically acceptable salt thereof, (b) tazobactam or a pharmaceutically acceptable salt thereof; and (c) an aminocarboxylic acid chelating agent or a pharmaceutically acceptable salt thereof, wherein the aminocarboxylic acid chelating agent is at least one compound selected from the group consisting of O,O'-bis(2-aminoethyl)ethyleneglycol-N,N,N',N'-tetraacetic acid (EGTA) and trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CyDTA).
2. (Original) A pharmaceutical composition according to claim 1 further comprising a buffer adapted to maintain a pH within the range of 6.0 to 7.5.
3. (Original) A pharmaceutical composition according to claim 2 wherein the buffer is adapted to maintain a pH of substantially 6.5.
4. (Original) A pharmaceutical composition according to claim 2 wherein the buffer is citrate.
5. (Original) A pharmaceutical composition according to claim 1 containing piperacillin sodium, tazobactam sodium and a sodium salt of the aminocarboxylic acid chelating agent.
6. (Original) A pharmaceutical composition according to claim 5 further comprising sodium citrate as buffer.
- 7-37. (Cancelled)
38. (Currently Amended) A pharmaceutical composition according to claim 1 further comprising an aminoglycoside selected from amikacin.
39. (Cancelled)
40. (Currently Amended) A pharmaceutical composition according to claim 6 further comprising an aminoglycoside selected from amikacin.

41. (Cancelled)
42. (Previously Presented) A pharmaceutical composition according to claim 1, wherein the composition is in the form of a powder that can be reconstituted by addition of a compatible reconstitution diluent prior to parenteral administration.
43. (Previously Presented) A pharmaceutical composition according to claim 6, wherein the composition is in the form of a powder that can be reconstituted by addition of a compatible reconstitution diluent prior to parenteral administration.
44. (Previously Presented) A pharmaceutical composition according to claim 1, wherein the composition is in the form of a frozen composition adapted to be thawed and, if desired, diluted with a compatible diluent prior to parenteral administration.
45. (Previously Presented) A pharmaceutical composition according to claim 6, wherein the composition is in the form of a frozen composition adapted to be thawed and, if desired, diluted with a compatible diluent prior to parenteral administration.
46. (Previously Presented) A pharmaceutical composition according to claim 1, wherein the composition is in a form ready to use for parenteral administration.
47. (Previously Presented) A pharmaceutical composition according to claim 6, wherein the composition is in a form ready to use for parenteral administration.
48. (Previously Presented) A pharmaceutical composition according to claim 1, wherein the composition is in the form of a solution and the piperacillin is present in an amount from about 8 mg/ml to about 500 mg/ml.
49. (Previously Presented) A pharmaceutical composition according to claim 6, wherein the composition is in the form of a solution and the piperacillin is present in an amount from about 8 mg/ml to about 500 mg/ml.
50. (Previously Presented) A pharmaceutical composition according to claim 1, wherein the composition is in the form of a solution and the tazobactam is present in an amount from about 0.1 mg/ml to about 125 mg/ml.
51. (Previously Presented) A pharmaceutical composition according to claim 6, wherein the composition is in the form of a solution and the tazobactam is present in an amount from about 0.1 mg/ml to about 125 mg/ml.

52. (Previously Presented) A pharmaceutical composition of claim 6, wherein the composition is in the form of a solution and the citrate buffer is present in an amount from about 0.25 mg/ml to about 25 mg/ml.
53. (Previously Presented) A pharmaceutical composition according to claim 1, wherein the composition is in the form of a solution, said composition further comprising an effective amount of dextrose to render the composition physiologically isosmotic.
54. (Previously Presented) A pharmaceutical composition according to claim 53, wherein the effective amount of dextrose is from about 5 mg/ml to about 100 mg/ml.
55. (Currently Amended) A pharmaceutical composition according to claim ~~40~~ 44, wherein the composition is in the form of a solution and the amikacin is present in an amount from about 0.1 mg/ml to about 75 mg/ml.
56. (Cancelled)
57. (Previously Presented) A pharmaceutical composition according to claim 1, wherein the composition is in the form of a solution, and wherein the aminocarboxylic acid chelating agent is present in an amount of about 0.002 mg/ml to about 10 mg/ml.
58. (Previously Presented) A pharmaceutical composition according to claim 57, wherein the aminocarboxylic acid chelating agent is present in an amount of about 0.003 mg/ml to about 1 mg/ml.
59. (Previously Presented) A pharmaceutical composition according to claim 1, wherein said pharmaceutical composition is a dose concentrate in a sealed container wherein said container has a space sufficient for introduction of a volume of aqueous solvent sufficient to form a concentrated solution of said pharmaceutical composition.
60. (Previously Presented) A pharmaceutical composition according to claim 6, wherein said pharmaceutical composition is a dose concentrate in a sealed container wherein said container has a space sufficient for introduction of a volume of aqueous solvent sufficient to form a concentrated solution of said pharmaceutical composition.
61. (Previously Presented) A pharmaceutical composition according to claim 1, wherein said pharmaceutical composition is in the form of a solution and is a unit dose contained in an IV bag or IV bottle for intravenous administration.

62. (Previously Presented) A process for the manufacture of a reconstitutable pharmaceutical composition in the form of a powder which process comprises the steps of:
- (a) dissolving effective amounts of piperacillin or a pharmaceutically acceptable salt thereof, tazobactam or a pharmaceutically acceptable salt thereof, and an aminocarboxylic acid chelating agent or a pharmaceutically acceptable salt thereof in an aqueous solvent to form a solution, wherein the aminocarboxylic acid chelating agent is at least one compound selected from the group consisting of O,O'-bis(2-aminoethyl)ethyleneglycol-N,N,N',N'-tetraacetic acid (EGTA) and trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CyDTA);
 - (b) adjusting the pH of said solution in the range of about 6.0 to about 7.5; and
 - (c) freeze drying said solution to form a reconstitutable powder.
63. (Currently Amended) The process according to claim 62 further comprising in step (a) dissolving an aminoglycoside selected from amikacin with said piperacillin, tazobactam and aminocarboxylic acid chelating agent.
64. (Cancelled)
65. (Currently Amended) The process according to claim ~~63~~ 64, wherein the ~~aminoglycoside is amikacin and~~ is present in an amount of about 0.1 mg/mL to about 75 mg/mL.
66. (Cancelled)
67. (Previously Presented) The process according to claim 62 further comprising in step (b) the pH is adjusted to about 6.5 with an effective amount of a buffer.
68. (Previously Presented) The process according to claim 67, wherein the buffer is citrate.
69. (Previously Presented) The process according to claim 67, wherein the buffer is sodium citrate.
70. (Previously Presented) A method for the treatment or control of bacterial infections in a mammal, said infections being caused by piperacillin/tazobactam susceptible bacteria wherein the method comprises parenteral administration of a therapeutically effective amount of the pharmaceutical composition of claim 1 to said mammal.

71. (Previously Presented) A method for the treatment or control of bacterial infections in a mammal, said infections being caused by piperacillin/tazobactam susceptible bacteria wherein the method comprises parenteral administration of a therapeutically effective amount of the pharmaceutical composition of claim 6 to said mammal.
72. (Currently Amended) A method for the treatment or control of bacterial infections in a mammal, said infections being caused by piperacillin/tazobactam susceptible bacteria wherein the method comprises parenteral co-administration of a therapeutically effective amount of the pharmaceutical composition of claim 1 and an aminoglycoside selected from amikacin to said mammal.
73. (Currently Amended) A method for the treatment or control of bacterial infections in a mammal, said infections being caused by piperacillin/tazobactam susceptible bacteria wherein the method comprises parenteral co-administration of a therapeutically effective amount of the pharmaceutical composition of claim 6 and an aminoglycoside selected from amikacin to said mammal.
74. (Cancelled)
75. (Cancelled)